Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of February 2020, with the report dated February 25, 2020. The filing primarily announces a significant non-dilutive financing agreement entered into on February 23, 2020, by the Company's wholly-owned subsidiary, RedHill Biopharma Inc. ("RedHill US"), with HCR Collateral Management, LLC and associated lenders.
Key Financial Metrics and Capital Structure
The filing details a credit facility with a total potential value of $115 million, structured in tranches:
- Initial Tranche: $30 million loan expected within approximately 12 business days.
- Second Tranche: $50 million loan contingent on funding the acquisition of rights to Movantik from AstraZeneca.
- Additional Tranches: $20 million and $15 million available upon satisfaction of specific conditions, including the funding of prior tranches.
Cost of Capital and Terms:
- Interest Rate: 3-month LIBOR plus 8.20% (with a 1.75% LIBOR floor). The margin may step down to 6.70% if trailing four-quarter net revenues for the fiscal quarter ending March 31, 2021, equal or exceed $38 million.
- Royalty: HCR receives a royalty on up to $75 million of annual worldwide net revenues. The rate is 2% if only the first tranche is drawn, 4% if the second tranche is drawn, and 4.5% if the final tranche is drawn.
- Maturity: Six years with no principal amortization required in the first three years, provided certain net revenue targets are met.
- Collateral: Secured by assets of RedHill US, pledged shares of RedHill US, and Company assets related to Talicia.
The filing text does not provide specific values for current revenue, profit, cash flow, or existing debt levels outside of the new facility terms.
Material Changes and Covenants
The primary material change is the establishment of the $115 million credit facility. The agreement includes several restrictive covenants:
- Liquidity Covenant: The Company must maintain a specified level of cash liquidity.
- Revenue Covenant: A requirement to maintain minimum net sales beginning with the fiscal quarter ending June 30, 2022.
- Key Personnel Covenant: Restrictions on terminating or changing the roles of CEO Dror Ben-Asher and RedHill US Chief Commercial Officer Rick Scruggs as of February 23, 2020.
Outlook, Risks, and Contingencies
Outlook and Strategy: The financing is intended to fund operations and the potential acquisition of Movantik. Management anticipates the ability to commercialize Talicia, Aemcolo, and potentially Movantik.
Risks and Contingencies: The filing highlights numerous forward-looking risks, including:
- Timing and success of the Movantik acquisition.
- Commercial launch timing and market acceptance of Talicia and other therapeutic candidates.
- Regulatory approvals and clinical trial results.
- Ability to meet the financial covenants (revenue targets and liquidity levels) required to avoid default.
- Intellectual property disputes and competition.
Investor Verification Checklist
- Verify the closing status of the initial $30 million tranche and the satisfaction of conditions precedent.
- Confirm the regulatory and commercial status of the proposed Movantik acquisition from AstraZeneca.
- Monitor the Company's ability to meet the $38 million trailing four-quarter net revenue target to secure the lower interest rate tier.
- Review the Company's cash liquidity position to ensure compliance with the new financial covenant.
- Assess the commercialization progress of Talicia, which serves as collateral for the facility.